# A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

> **NCT03761849** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 899 (actual)

## Conditions studied

- Huntingtons Disease

## Interventions

- **DRUG:** RO7234292
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03761849
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-23
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-03-24
- **Target enrollment:** 899 (ACTUAL)
- **Last updated:** 2024-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03761849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03761849, "A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03761849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*